NASDAQ$AKBA
Akebia Therapeutics Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Akebia reported fourth quarter and full-year 2020 financial results and provided business updates.
Akebia Therapeutics reported a Q4 2020 total revenue of $56.7 million, a decrease compared to $69.6 million in Q4 2019. The net loss was $87.0 million, slightly better than the $94.5 million net loss in the same quarter of the previous year. The company's cash position remained strong with $268.7 million in cash, cash equivalents, and available-for-sale securities.
- Total revenue for Q4 2020 was $56.7 million, compared to $69.6 million for Q4 2019.
- Net product revenue increased to $34.6 million for Q4 2020, up from $28.9 million for Q4 2019.
- Net loss for Q4 2020 was $87.0 million, compared to $94.5 million for Q4 2019.
- Cash, cash equivalents and available-for-sale securities totaled $268.7 million as of December 31, 2020.
Headline financials
Revenue & EPS history
Akebia · Revenue · Quarterly
$56.7M
Revenue by segment
Akebia · $56.7M total across 2 segments · Q4 2020
- Auryxia$34.6M+19.7%61.0%
- License & other revenue$22.1M-45.6%39.0%
Forward guidance
Akebia anticipates that the COVID-19 pandemic will continue to negatively impact Auryxia revenue growth due to higher hospitalization and mortality rates among kidney patient populations. The company is focused on improving its cost structure and maintaining a strong balance sheet, as evidenced by the recent royalty transaction with HCR. Akebia expects its cash resources to fund its operating plan beyond the anticipated U.S. launch of vadadustat.
Tailwinds
- Focus on improving cost structure.
- Maintaining a strong balance sheet.
- Recent $60 million non-dilutive royalty transaction with HCR.
- Cash resources expected to fund the operating plan beyond vadadustat launch.
- Advancing vadadustat toward commercialization.
Headwinds
- COVID-19 continues to adversely impact the patient population.
- Expectation of negative impact on future Auryxia revenue growth.
- Higher hospitalization rates among kidney patient populations.
- Higher mortality rates among kidney patient populations.
- Unable to fully quantify the impact of COVID-19 on future revenues.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-2.5%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-2.1%
Avg return
30 days after
41%
19 / 46 earnings
Positive
+34.4%
Q1 2020
Best reaction
-22.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -20.3% | -20.3% | -36.7% | |
| Q4 2025 | +9.9% | +0.8% | +10.7% | |
| Q3 2025 | -18.4% | -18.1% | -20.1% | |
| Q1 2025 | +6.6% | +0.8% | +61.4% | |
| Q4 2024 | -12.4% | +32.1% | -14.5% | |
| Q3 2024 | -3.0% | -2.5% | +2.5% | |
| Q2 2024 | +0.0% | +20.7% | +21.6% | |
| Q1 2024 | -13.6% | -12.1% | -24.3% | |
| Q4 2023 | +20.6% | +29.8% | +3.5% | |
| Q3 2023 | -16.5% | -15.3% | +3.7% | |
| Q2 2023 | +10.4% | +12.0% | -5.6% | |
| Q1 2023 | -3.7% | +3.7% | +17.4% | |
| Q4 2022 | -22.4% | -33.7% | -47.6% | |
| Q3 2022 | +1.9% | +2.6% | +9.0% | |
| Q2 2022 | +1.0% | +3.6% | -2.8% | |
| Q1 2022 | +11.2% | +16.6% | +15.6% | |
| Q4 2021 | +13.4% | +12.0% | -66.8% | |
| Q3 2021 | -12.3% | -14.4% | -24.6% | |
| Q2 2021 | +10.5% | +6.5% | +22.2% | |
| Q1 2021 | +2.6% | +10.6% | +17.9% | |
| Q4 2020 | -19.2% | -17.5% | -26.2% | |
| Q3 2020 | -7.4% | +0.8% | +19.8% | |
| Q2 2020 | -6.4% | -4.1% | -75.9% | |
| Q1 2020 | +34.4% | +38.3% | +40.6% | |
| Q4 2019 | -13.8% | -27.0% | -13.0% | |
| Q3 2019 | -9.6% | -8.2% | +73.5% | |
| Q2 2019 | +20.5% | +22.4% | +11.2% | |
| Q1 2019 | +1.5% | -0.7% | -26.8% | |
| Q4 2018 | -0.9% | +2.7% | -15.3% | |
| Q3 2018 | +10.3% | -4.2% | +5.0% | |
| Q2 2018 | -18.1% | -22.1% | -20.8% | |
| Q1 2018 | +0.7% | +11.0% | +10.5% | |
| Q4 2017 | -10.6% | -12.6% | -28.9% | |
| Q3 2017 | -12.6% | -12.8% | -8.5% | |
| Q2 2017 | +6.8% | +9.4% | +26.0% | |
| Q1 2017 | -2.3% | +2.2% | +8.2% | |
| Q4 2016 | -12.6% | -9.3% | -11.1% | |
| Q3 2016 | +10.6% | +14.1% | +9.9% | |
| Q2 2016 | -9.6% | -7.4% | -3.8% | |
| Q1 2016 | -8.8% | — | — | |
| Q4 2015 | -2.4% | — | — | |
| Q3 2015 | -16.6% | — | — | |
| Q2 2015 | -16.9% | — | — | |
| Q1 2015 | +3.3% | — | — | |
| Q3 2014 | -3.2% | — | — | |
| Q1 2014 | +3.7% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro